2STEINER TJ, DELLAPORTAS CI, FINDLEY LJ, et al Lamolrigine monotherapy in newly diagnosed untreated epilepsy a double-blind comparison with phenytoin[J]. Epilepsia, 1999 40(5) : 601-607.
3NIETO-BARRERA M, BROZMANOVA M, CAPOVILLA G, etal. A comparison of monotherapy with lamotrigine or carbama-zepine in patients with newly diagnosed partial epilepsy[J]. Epilepsy Res, 2001, 46(2): 145-155.
4WHELESS JW, CLARKE DF, ARZIMANOGLOU A, et al. Treatment of pediatric epilepsy: European expert opinion, 2007 [J]. Epileptic Disord, 2007, 9(4): 353-412.
6FRENCH JA, KANNER AM, BAUISTA J, et al. Efficacy and tolerability of the new antiepileptic drugs Ⅱ : treatment of re-fractory epilepsy: report of the Therapeutics and Technology As- sessment Subcommittee and Quality Standards Subcommittee ofthe American Academy Neurology and the American Epilepsy Society[J]. Neurology, 2004, 62(8): 1261-1273.
7SCHLUMBERGER E, CHAVEZ F, PALACIOS L, et al. Lamotrigine in treatment of 120 children with epilepsy[J]. Epi- lepsia, 1994, 35(2) : 359-367.
8MATSUO F, GAY P, MADSEN J, et al. Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study[J]. Epilepsia, 1996, 37 (9) : 857-862.
9WONG IC, MAWER GE, SANDER JW. Adverse event mo- nitoring in lamotrigine patients: a pharmacoepidemiologic studyin the United Kingdom[J]. Epilepsia, 2001, 42(2) : 237-244.
10WONG IC, MAWER GE, SANDER JW. Factors influencing the incidence of lamotrigine-related skin rash[J]. Ann Pharmaeo- ther, 1999, 33(10): 1037-1042.
